Genetic code expansion (GCE) allows the site-specific incorporation of non-canonical amino acids (ncAAs), which serve as new building blocks for studying and altering proteins. Leveraging the innovative GCEngine platform with deep expertise in preclinical services, our company empowers pharmaceutical researchers to overcome traditional limitations in drug discovery and development. By enabling the site-specific incorporation of ncAAs into target proteins, this cutting-edge technology facilitates the creation of novel molecular entities with enhanced properties, supporting the development of next-generation therapeutics.
GCE technology provides a foundational technology for designing the next generation of biologics. By enabling the site-specific incorporation of ncAAs, it unlocks a diverse array of powerful applications critical to modern drug development.
Fig.1 Enabling next-generation antibody therapeutics through GCE. (Huang, Y., and Liu, T., 2018)
Offering a comprehensive, end-to-end solution specifically tailored for pharmaceutical challenges, our company leverages a high-throughput discovery platform for orthogonal aaRS/tRNA pairs, tailored to client-specified ncAAs, followed by rigorous in vitro validation and in vivo application to ensure efficient incorporation into therapeutic proteins of interest, delivering a complete, end-to-end solution for pioneering pharmaceutical projects. We help you move from concept to qualified reagents and preclinical-ready prototypes with traceable data packages, reducing iteration cycles and de-risking downstream translation.
Leveraging our proprietary GCEngine technology platform, we provide specialized services designed to accelerate and enhance pharmaceutical research and development:
The versatility of the GCEngine platform enables its application across a broad range of disease areas and therapeutic modalities. We collaborate with you to develop tailored solutions, whether targeting a specific pathological condition or creating novel molecular entities.
By Disease Area
The GCEngine platform delivers targeted solutions across major disease areas, facilitating the development of next-generation therapeutics with improved targeting and innovative mechanisms of action.
By Molecular Types
Utilizing the unique chemistry of ncAAs, we facilitate the precise engineering of diverse therapeutic modalities, from peptides to complex antibodies, to overcome limitations inherent in natural biologics.
By integrating a state-of-the-art GCEngine platform with extensive pharmaceutical science expertise, we deliver seamless, customized solutions that accelerate development timelines and foster therapeutic innovation. From concept to validation, we provide robust technical support and reliable data generation to help our partners achieve groundbreaking discoveries. To learn more about how our services can advance your project, contact us today for a collaborative consultation.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.